Targeting HER2 beyond progression in gastroesophageal cancer

Affiliations

¹ Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: hanna_sanoff@med.unc.edu.

Comment

Hanna K Sanoff. Lancet Oncol. 2017 May.

. 2017 May;18(5):562-564.

doi: 10.1016/S1470-2045(17)30102-X. Epub 2017 Mar 23.

¹ Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: hanna_sanoff@med.unc.edu.

No abstract available

Comment on

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK. Thuss-Patience PC, et al. Lancet Oncol. 2017 May;18(5):640-653. doi: 10.1016/S1470-2045(17)30111-0. Epub 2017 Mar 23. Lancet Oncol. 2017. PMID: 28343975 Clinical Trial.